This "first-in-human" exploratory IND, single-center study will assess the safety, toxicity, hematology, and immunogenicity of sub-therapeutic "microdoses" of autologous Thrombosomes® in healthy human subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
15
Freeze-dried platelets
Bloodworks Northwest
Seattle, Washington, United States
Number of Participants with Adverse Events as a Measure of Safety Evaluation
Time frame: 60 days
Standard Hematology, Coagulation and Platelet Immunology Assessment
Time frame: 60 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.